Lacosamide Oral Solution
Product Images NDC 73190-103

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide Oral Solution (NDC 73190-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (103 20)

Label for Lacosamide Oral Solution, USP 10 mg/mL by AvKARE. The label indicates a 200 mL bottle size and includes storage instructions, dosage note, and a warning to keep out of reach of children. The label also states it is a prescription-only human drug, with the AvKARE logo and barcode present.*

FDA Label Image

Lacofig1 (Laco Fig 1)

Bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' showing seizure reduction percentages in three separate studies comparing placebo and different lacosamide doses. Y-axis measures median percent reduction from 0% to 45%. Each study includes bars for placebo and lacosamide doses with corresponding median reduction percentages above bars, highlighting statistically significant differences compared to placebo with an asterisk.*

FDA Label Image

Lacofig2a (Laco Fig 2a)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide Oral Solution and Placebo Groups in Studies 2, 3, and 4.' The x-axis shows Percent of Patients from 0 to 100, and the y-axis shows Responder Rate ranging from -100% (worsening) to 100% (improvement). Four lines represent Placebo and Lacosamide doses of 200 mg/day, 400 mg/day, and 600 mg/day, showing the relationship between patient percent and responder rate for each group.*

FDA Label Image

Lacostructure (Laco Structur)

Chemical structure of lacosamide, the active ingredient in Lacosamide Oral Solution 10 mg/mL by AvKARE.*

FDA Label Image

Lacofig3 (Lacofig3)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between two groups: Lacosamide (dashed line) and Placebo (solid line). The graph includes statistical data showing a significant difference in patient outcomes, with a p-value of 0.001 and a hazard ratio indicating a 45.2% risk reduction for Lacosamide compared to Placebo. The number of patients at risk is displayed below the time axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.